Hepatitis B Virus Immunity Level in Relation to Vaccine Schedule Among Medical Laboratory Health Care Providers In Machakos County Kenya
Hepatitis B Virus HBV is categorized in the genus orthohepadnae virus and it encompasses double stranded DNA virus. Viral infection caused by HBV can either be acute or chronic infection. Acute type of HBV infection occurs in the initial six months from birth due to exposure to HBV and in adults there might be no symptoms and no complaint of any clinical signs or symptoms.
Study design used was a cross-sectional study involving all Medical laboratory health care providers was conducted. Hepatitis B Virus surface antigen rapid test and enzyme linked immunosorbent assay ELISA test were used to test the blood samples collected from the subjects and the results were analysed using chi-square and verified using Pearson Correlation Coefficient.
The study found that the number of participants who were unvaccinated were 1617.39 of which 2 had protective immunity and 1466.66 had low immunity level. Participants who had received first dose of HBV vaccine were 12 of which 314.28 had low immunity level while 912.5 had protective immunity level. Participants who had received second doses of the vaccine were 1111.96 of 29.52 had low HBV immunity level where as 912.5 had protective immunity level. Participants who had complete HBV vaccine doses 3 doses were 5256.52 of which 29.52 had low immunity level while 5070.42 had protective immunity level.
The research concluded there is need for completion of HBV vaccine schedule of the three doses so as to increase the immunity level since 70.42 of respondents who had completed the three doses had protective immunity levels above the cutoff point recommended by the WHO 10 mIU/ml.
Publication Information
Focus County(s):
Machakos County
Programme Area(s):
Infectious and Parasitic Diseases
Research Priority Area(s):
Disease Domain(s):
Hepatitis B Virus
Document History:
Publication Date: 17.Nov.2022
Conference Title: